Setrusumab is a monoclonal antibody that inhibits sclerostin, a protein that negatively regulates bone development, allowing for new bone formation.
NextCure, Inc. has presented new preclinical data at the Brittle Bone Society Meeting showing that its novel anti-Siglec-15 antibody, NC605, significantly improves bone microarchitecture and reduces ...
A study conducted by researchers at Baylor College of Medicine and collaborating institutions reveals the molecular events leading to osteogenesis imperfecta type V, a form of brittle bone disease ...
Zacks Investment Research on MSN
Rare, MREO tank as osteogenesis study fails to meet primary endpoint
Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the companies announced disappointing data from the phase III Orbit and Cosmic ...
Wif1 overexpression accelerated osteogenic differentiation by activating genes related to late-stage osteogenic differentiation and mitophagy processes. Moreover administering Wif1-overexpressing ...
Ultragenyx Pharmaceutical said on Monday late-stage studies showed its experimental drug for a type of genetic bone disease failed to reduce the number of fractures that occurred per year. Shares of ...
Schematic diagram illustrating how transplanted young mitochondria activate the AKAP1/cAMP/PKA pathway in aged PDLSCs, restoring mitochondrial membrane potential (ΔΨm), reducing ROS, and enhancing ...
Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP ...
About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback